Theriva Biologics, Inc. stock is down -0.14% since 30 days ago. The next earnings date is Mar 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.94% of the previous 30 December’s closed higher than November.
Synthetic Biologics, Inc. develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade intravenous beta-lactam antibiotics in gastrointestinal (GI) tract. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.